SCHEMBL7049798

SCHEMBL7049798

CC(=O)CC(On1nnc2ccccc21)N1CCN(c2ncnc3sc(Cc4ccccc4)cc23)CC1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.47
P2RY12 Q9H244 6/20 0.47
KMT2A Q03164 4/20 0.44
ALDH1A1 P00352 4/20 0.43
HTT P42858 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
TP53 P04637 1/20 0.43
MAPT P10636 1/20 0.43
TSHR P16473 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
KDM4E B2RXH2 2/20 0.41
AKT1 P31749 2/20 0.38
AKT2 P31751 2/20 0.38
AKT3 Q9Y243 2/20 0.38
LMNA P02545 1/20 0.38
GAA P10253 1/20 0.38
STAT3 P40763 1/20 0.38
PDGFRB P09619 1/20 0.38
HRH4 Q9H3N8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7052594 0.92 MEN1 (0.53) MEN1P2RY12KMT2AALDH1A1HTT
SCHEMBL7050290 0.88 KDM4E (0.56) MEN1P2RY12KMT2AALDH1A1HTT
SCHEMBL7053832 0.85 ALDH1A1 (0.39) MEN1P2RY12KMT2AALDH1A1HTT
SCHEMBL7053767 0.80 P2RY12 (0.38) MEN1P2RY12KMT2AALDH1A1
SCHEMBL7052654 0.80 P2RY12 (0.43) MEN1P2RY12
SCHEMBL7052962 0.78 KMT2A (0.40) MEN1KMT2AALDH1A1HTTSMN1; SMN2
SCHEMBL5850838 0.78 P2RY12 (0.53) MEN1P2RY12KMT2AALDH1A1HTT
SCHEMBL7054311 0.78 HTT (0.41) MEN1P2RY12KMT2AALDH1A1HTT
SCHEMBL7052685 0.77 SMN1; SMN2 (0.53) MEN1P2RY12KMT2AALDH1A1HTT
SCHEMBL7063523 0.73 P2RY12 (0.68) MEN1P2RY12KMT2AALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2003022214-A2 PIPERAZINE AND HOMOPIPERAZINE COMPOUNDS MILLENNIUM PHARMACEUTICALS, INC. (US) 2003-03-20 WO disclosed